Purpose Radioimmunotherapy (RIT) is a new treatment option for patients with non-Hodgkin
lymphoma (NHL). Response to RIT currently remains difficult to predict using conventional …

PET imaging has evolved as an indispensible tool for staging in oncology. Multiple
quantitative measurements can be performed, enabling the effects of treatment to be …

Background Currently, only a fraction of patients with non-small cell lung cancer (NSCLC)
treated with immune checkpoint inhibitors (ICIs) experience a durable clinical benefit (DCB) …

In the past, enormous public and private investments have been made to reduce cancer
incidence and mortality. Despite some improvements over the last 10 years, the overall …

Response assessment or prediction to checkpoint inhibitor therapy (CIT) is an unsolved
problem in current routine diagnostics of patients with melanoma. Here, we evaluated very …

Abstract Background Immune checkpoint inhibitors (ICIs) have significantly improved
survival in advanced melanoma. There is a need for robust biomarkers to identify patients …

Lymphoma is a heterogeneous group of diseases with many curable subtypes. Primary
treatment cures a significant proportion of, but not all, patients. Patients not achieving a …

We describe methods and issues that are relevant to the measurement of change in tumor
uptake of 18 F-fluorodeoxyglucose (FDG) or other radiotracers, as measured from positron …

Lymphomas are heterogeneous but potentially curable group of neoplasms. Treatment of
lymphomas has rapidly evolved overtime with significant improvement in the cure rate and …

Molecular Imaging has played a prominent role in the assessment of lymphoma for now
almost three decades since the introduction of 67 Ga-citrate imaging for staging and …